Article
Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.
Gastroenterology - 1 Jun 2018
Roy Somak, LaFramboise William A, Liu Ta-Chiang, Cao Dengfeng, Luvison Alyssa, Miller Caitlyn, Lyons Maureen A, O'Sullivan Roderick J, Zureikat Amer H, Hogg Melissa E, Tsung Allan, Lee Kenneth K, Bahary Nathan, Brand Randall E, Chennat Jennifer S, Fasanella Kenneth E, McGrath Kevin, Nikiforova Marina N, Papachristou Georgios I, Slivka Adam, Zeh Herbert J, Singhi Aatur D
Abstract excerpt
Despite prognostic grading and staging systems, it is a challenge to predict outcomes for patients with pancreatic neuroendocrine tumors (PanNETs). Sequencing studies of PanNETs have identified alterations in death domain-associated protein (DAXX) and alpha-thalassemia/mental retardation X-linked chromatin remodeler (ATRX). In tumors, mutations in DAXX or ATRX and corresponding loss of protein expression...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.